ICAAC 2010
Does CD4 Cell Count Influence Liver Fibrosis in HIV/HCV Coinfected People?
- Details
- Category: HCV Disease Progression
- Published on Friday, 01 October 2010 12:46
- Written by Liz Highleyman
Neither current nor lowest-ever CD4 T-cell levels were associated with hepatitis C virus (HCV) viral load or severity of liver fibrosis in HIV positive people after adjusting for other factors, according to a Spanish study presented at the recent 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) in Boston.
Tesamorelin Growth Hormone-releasing Factor Reduces Visceral Fat in Diverse Patient Groups
- Details
- Category: HIV-Related Conditions
- Published on Tuesday, 28 September 2010 13:46
- Written by Liz Highleyman
Tesamorelin (TH9507, brand name Egrifta), a recombinant form of human growth hormone-releasing factor, decreased the amount of visceral abdominal fat over 1 year in a variety of sub-populations of HIV patients with lipodystrophy, according to research presented at the recent 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010). A related study found that fat loss measured by CT scans was reflected in reduced waist size and improved patient-reported body image.
Rilpivirine Failure Linked to High Viral Load and Poor Adherence
- Details
- Category: HIV Treatment
- Published on Friday, 24 September 2010 13:46
- Written by Liz Highleyman
High baseline viral load and less-than-optimal adherence help explain the higher rate of virological failure among people taking Tibotec's experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (TMC278) in a pair of recent clinical trials, according to findings presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) last week in Boston. Rilpivirine recipients were less likely than efavirenz recipients to stop treatment due to side effects, but more likely to develop drug-resistance mutations.
Lymphoma Chemotherapy Can Cause Severe Hepatitis B Reactivation
- Details
- Category: HBV-Related Conditions
- Published on Tuesday, 28 September 2010 12:46
- Written by Liz Highleyman
Chronic hepatitis B patients are at risk for recurrence or relapse when they undergo chemotherapy for lymphoma, despite receiving prophylaxis with lamivudine (Epivir-HBV), according to an Italian study presented at the recent 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) in Boston. Investigators recommended that other potentially more effective antiviral drugs should be studied for this indication.
Nearly 20% of New Hepatitis B Infections May Occur in Healthcare Settings
- Details
- Category: HBV Prevention
- Published on Friday, 24 September 2010 12:46
- Written by Liz Highleyman
As many as 1 in 5 cases of acute hepatitis B virus (HBV) infection in the U.S. may be attributable to exposure in healthcare settings, especially long-term care facilities, according to research presented last week at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) in Boston.
More Articles...
- Maraviroc Failure with Co-receptor Switch Does Not Lead to HIV Disease Progression
- End-of-Treatment Response to Interferon-based Therapy Reduces Liver Failure and Death in HIV/HCV Coinfected Patients
- Worse Fibrosis Predicts Death in HIV/HCV Coinfected Individuals, Interferon Therapy Lowers Risk
- Use of CCR5 Antagonist Does Not Explain Better CD4 Cell Recovery with Newer Antiretroviral Drugs
Web Design and Development by